On Buying Spree, Colby Pharma Builds A Clinical Stage Portfolio
This article was originally published in The Pink Sheet Daily
Executive Summary
The privately-held Colby Pharmaceutical Company is building a portfolio of drugs through several in-licensing deals, the latest of which is with Mannkind for rights to disease-specific antigen compounds and intra-lymph node delivery technologies from a novel cancer immunotherapy program.